The University of Chicago Header Logo

Connection

Richard Larson to Idarubicin

Back to Details
This is a "connection" page, showing publications Richard Larson has written about Idarubicin.
Richard Larson
Connection Strength
0.073
Idarubicin
  1. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia. 2024 01; 38(1):58-66.
    View in: PubMed
    Score: 0.052
  2. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res. 2011 Mar; 35(3):329-33.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.